openPR Logo
Press release

Tempus AI, Inc. (NASDAQ: TEM) Shareholder Notice: Deadline in Lawsuit on August 12, 2025

A Deadline is coming up on August 12, 2025 in the lawsuit for certain investors in Tempus AI, Inc. (NASDAQ: TEM).

A Deadline is coming up on August 12, 2025 in the lawsuit for certain investors in Tempus AI, Inc. (NASDAQ: TEM).

The Shareholders Foundation announced that a deadline is coming up on August 12, 2025 in the lawsuit filed for certain investors of Tempus AI, Inc. (NASDAQ: TEM) over alleged securities laws violations by Tempus AI, Inc.

Investors who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and there are strict and short deadlines running. Deadline: August 12, 2025. NASDAQ: TEM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges on behalf of purchasers of Tempus AI, Inc. (NASDAQ: TEM) common shares between August 6, 2024 and May 27, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2024 and May 27, 2025, Tempus AI, Inc. branded itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements, that the Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding, that Tempus AI, Inc. often reported on its relationship with long-term customer AstraZeneca as an example, that importantly between August 6, 2024 and May 27, 2025, Tempus AI, Inc. announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI, that the Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market, that Tempus AI, Inc. additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired between August 6, 2024 and May 27, 2025, and that Tempus AI, Inc. claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.

Those who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tempus AI, Inc. (NASDAQ: TEM) Shareholder Notice: Deadline in Lawsuit on August 12, 2025 here

News-ID: 4142884 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Tempus

Genomics In Cancer Care Market is Booming Worldwide |Invitae,Helix, Tempus
HTF MI just released the Global Genomics In Cancer Care Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major Manufacturers are covered: Foundation Medicine (United States), Guardant
Predictive Disease Analytics Market Is Booming So Rapidly | Tempus, Verily, Pala …
The Global Predictive Disease Analytics Market Size is estimated at $3.5 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 21.4% to reach $20 Billion by 2034. The latest study released on the Global Predictive Disease Analytics Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Predictive Disease Analytics market study covers significant research data and proofs to be a handy
AI in Medical Diagnostics Market Is Booming So Rapidly | Aidoc, Tempus, Lunit
USD Analytics recently introduced Global AI in Medical Diagnostics Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, GE Healthcare, Siemens Healthineers, Zebra
AI in Oncology Market SWOT Analysis by Leading Expert: Tempus, Oncora, PerkinElm …
USD Analytics recently introduced Global AI in Oncology Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, Tempus, GE Healthcare, Siemens Healthineers, Varian
Artificial Intelligence In Precision Medicine Market Is Booming So Rapidly: IBM, …
The latest study released on the Global Artificial Intelligence In Precision Medicine Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Artificial Intelligence In Precision Medicine market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming
Medical Dataplace Services Market Growth Drivers, and Competitive Landscape |Hum …
The Medical Dataplace Services Market research report represents major insights on the current growth dynamics as well as the primary revenue generation elements that are available in the Medical Dataplace Services industry along with various other factors over the predicted period 2023-2030. The report on the Medical Dataplace Services market is focusing on a series of parameters including top manufacturing strategies, industry share, prime opportunities, industrial channels, profit margin, etc.